“…Although conventional therapeutic modalities are effective in early-stage thyroid cancer patients, they are largely ineffective in advanced stage patients with differentiated, undifferentiated/anaplastic or medullary thyroid cancers (DTC, ATC or MTC) [1–4]. Hence, there is an urgent need to discover, develop and critically evaluate novel therapeutic drugs to clinically treat thyroid cancer patients [4]. Thyroid cancers are associated with mutations in many critical genes like BRAF, RAS , catenin (cadherin-associated protein), beta 1, PIK3CA, TP53, AXIN1, PTEN , and APC [5].…”